Shire Submits Elaprase BLA For Hunter Syndrome
This article was originally published in Pharmaceutical Approvals Monthly
Shire's Elaprase (idursulfase) could be approved as early as May 2006 for Hunter syndrome if FDA grants the company's request for priority review of the BLA submission, announced Nov. 24
You may also be interested in...
Transkaryotic Therapies is planning a fourth-quarter BLA submission for its Hunter syndrome enzyme replacement therapy I2S, the firm said June 20
Shire addition of European rights to Dynepo is key driver of $1.6 bil. TKT merger. Roche’s Xenical to be detailed by GSK. Schering-Plough to out-license U.S. rights to Phase III quinolone antibiotic garenoxacin. Kos plans Teveten and Cardizem LA re-launch in June following purchase/licensing pact with Biovail. More licensing deals in brief
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011